vosevi
Generic: sofosbuvir, velpatasvir, and voxilaprevir
Labeler: gilead sciences, inc.Drug Facts
Product Profile
Brand Name
vosevi
Generic Name
sofosbuvir, velpatasvir, and voxilaprevir
Labeler
gilead sciences, inc.
Dosage Form
TABLET, FILM COATED
Routes
Active Ingredients
sofosbuvir 400 mg/1, velpatasvir 100 mg/1, voxilaprevir 100 mg/1
Manufacturer
Identifiers & Regulatory
Product NDC
61958-2401
Product ID
61958-2401_6ce7dd60-defa-4530-bff3-de03885e318a
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
NDA
Application Number
NDA209195
Listing Expiration
2026-12-31
Marketing Start
2017-07-18
Pharmacologic Class
Established (EPC)
Mechanism of Action
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
619582401
Hyphenated Format
61958-2401
Supplemental Identifiers
RxCUI
UNII
NUI
Packaging Origin
Original Packager
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
vosevi (source: ndc)
Generic Name
sofosbuvir, velpatasvir, and voxilaprevir (source: ndc)
Application Number
NDA209195 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 400 mg/1
- 100 mg/1
Packaging
- 28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-2401-1)
Packages (1)
Ingredients (3)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "6ce7dd60-defa-4530-bff3-de03885e318a", "openfda": {"nui": ["N0000191493", "N0000191258", "N0000191256", "N0000190113", "N0000185503", "N0000190107", "N0000190108", "N0000190109", "N0000182639", "N0000182638"], "unii": ["WJ6CA3ZU8B", "KCU0C7RS7Z", "0570F37359"], "rxcui": ["1939329", "1939335"], "spl_set_id": ["17ffc094-8ca7-45d2-80d8-fd043bc9a221"], "pharm_class_epc": ["Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]", "Hepatitis C Virus NS5A Inhibitor [EPC]", "Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]"], "pharm_class_moa": ["RNA Replicase Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA]", "HCV NS3/4A Protease Inhibitors [MoA]"], "manufacturer_name": ["Gilead Sciences, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-2401-1)", "package_ndc": "61958-2401-1", "marketing_start_date": "20170718"}], "brand_name": "Vosevi", "product_id": "61958-2401_6ce7dd60-defa-4530-bff3-de03885e318a", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "HCV NS3/4A Protease Inhibitors [MoA]", "Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]", "Hepatitis C Virus NS5A Inhibitor [EPC]", "Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "RNA Replicase Inhibitors [MoA]"], "product_ndc": "61958-2401", "generic_name": "SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR", "labeler_name": "Gilead Sciences, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Vosevi", "active_ingredients": [{"name": "SOFOSBUVIR", "strength": "400 mg/1"}, {"name": "VELPATASVIR", "strength": "100 mg/1"}, {"name": "VOXILAPREVIR", "strength": "100 mg/1"}], "application_number": "NDA209195", "marketing_category": "NDA", "marketing_start_date": "20170718", "listing_expiration_date": "20261231"}